Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Common Equity: 2009-2024

Historic Common Equity for Gyre Therapeutics (GYRE) over the last 15 years, with Dec 2024 value amounting to $98.4 million.

  • Gyre Therapeutics' Common Equity rose 39.54% to $137.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.4 million, marking a year-over-year increase of 39.54%. This contributed to the annual value of $98.4 million for FY2024, which is 721.70% up from last year.
  • Latest data reveals that Gyre Therapeutics reported Common Equity of $98.4 million as of FY2024, which was up 721.70% from -$15.8 million recorded in FY2023.
  • In the past 5 years, Gyre Therapeutics' Common Equity registered a high of $98.4 million during FY2024, and its lowest value of -$15.8 million during FY2023.
  • Its 3-year average for Common Equity is $51.6 million, with a median of $72.2 million in 2022.
  • Per our database at Business Quant, Gyre Therapeutics' Common Equity crashed by 121.92% in 2023 and then skyrocketed by 721.70% in 2024.
  • Over the past 5 years, Gyre Therapeutics' Common Equity (Yearly) stood at $76.1 million in 2020, then crashed by 45.98% to $41.1 million in 2021, then surged by 75.76% to $72.2 million in 2022, then plummeted by 121.92% to -$15.8 million in 2023, then skyrocketed by 721.70% to $98.4 million in 2024.